| Pharmacokinetics of caffeic acid phenethyl ester and its catechol‐ring fluorinated derivative following intravenous administration to rats X Wang, J Pang, JA Maffucci, DS Pade, RA Newman, SM Kerwin, ... Biopharmaceutics & drug disposition 30 (5), 221-228, 2009 | 76 | 2009 |
| A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism … AS Darwich, D Pade, BJ Ammori, M Jamei, DM Ashcroft, ... Journal of Pharmacy and Pharmacology 64 (7), 1008-1024, 2012 | 68 | 2012 |
| Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon D Pade, M Jamei, A Rostami‐Hodjegan, DB Turner Biopharmaceutics & drug disposition 38 (2), 94-114, 2017 | 45 | 2017 |
| Evaluation of an In Silico PBPK Post‐Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine AS Darwich, D Pade, K Rowland‐Yeo, M Jamei, A Åsberg, H Christensen, ... CPT: pharmacometrics & systems pharmacology 2 (6), 1-9, 2013 | 33 | 2013 |
| Canine gastrointestinal physiology: Breeds variations that can influence drug absorption H Oswald, M Sharkey, D Pade, MN Martinez European Journal of Pharmaceutics and Biopharmaceutics 97, 192-203, 2015 | 21 | 2015 |
| Comparison of canine and human physiological factors: understanding interspecies differences that impact drug pharmacokinetics MN Martinez, JP Mochel, S Neuhoff, D Pade The AAPS journal 23 (3), 59, 2021 | 19 | 2021 |
| Selection of Bioavailability Markers for Herbal Extracts Based on In Silico Descriptors and Their Correlation to In Vitro Permeability D Pade, S Stavchansky Molecular Pharmaceutics 5 (4), 665-671, 2008 | 12 | 2008 |
| Population variability in animal health: Influence on dose‐exposure‐response relationships: Part II: Modelling and simulation MN Martinez, R Gehring, JP Mochel, D Pade, L Pelligand Journal of veterinary pharmacology and therapeutics 41 (4), E68-E76, 2018 | 11 | 2018 |
| Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics D Pade, M Jamei, DB Turner, B Mistry, MN Martinez European Journal of Pharmaceutics and Biopharmaceutics 141, 191-209, 2019 | 5 | 2019 |
| Considerations in the Extrapolation of Drug Toxicity Between Humans and Dogs MN Martinez, JP Mochel, D Pade Current Opinion in Toxicology, 2020 | 4 | 2020 |
| A mechanistic framework for the in silico prediction of regional passive gut wall permeability and its inter-individual variability in humans D Pade, M Jamei, A Rostami Hodjegan, DB Turner AAPS 2014 W 5106, 2014 | 4 | 2014 |
| Use of in silico predictors, solubility and permeability to select bioavailability and bioequivalence markers in herbal supplements DS Pade The University of Texas at Austin, 2007 | 4 | 2007 |
| Use of physiologically based pharmacokinetic (PBPK) models to support canine drug product development D Pade, M Martinez, B Mistry, M Jamei, A Rostami-Hodjegan Journal of Veterinary Pharmacology and Therapeutics 38 (Suppl. 1), 99, 2015 | 3 | 2015 |
| Use of in silico physiologically based pharmacokinetic (PBPK) models to predict food effects in dogs B Mistry, D Pade, A Rostami-Hodjegan, M Jamei, M Martinez The 2013 American Association of Pharmaceutical Scientists (AAPS) Annual …, 2013 | 2 | 2013 |
| Workshop report: USP workshop on exploring the science of drug absorption MN Martinez, S Bhoopathy, S Carlert, M Cirit, R Fahmy, T Flanagan, ... Dissolution Technologies 26 (3), 38-66, 2019 | 1 | 2019 |
| A performance evaluation of Simcyp Dog—A fully mechanistic physiologically based pharmacokinetic dog model based upon a variety of celecoxib IV and oral formulations D Pade, D Turner, M Jamei, L Antonovic, M Martinez, ... AAPS Annual Meeting; Washington, DC, 2011 | 1 | 2011 |
| A mechanistic PBPK model for Maraviroc to elucidate the dose related non-linearity in oral absorption using a middle out approach. D Pade, I Gardner, P Kilford AAPS PharmSci 360 Annual Meeting and Exposition Boston, MA, USA, 2022, M0930 …, 2022 | | 2022 |
| Development and Verification of a Physiologically Based Pharmacokinetic-Pharmacodynamic (PBPK-PD) Canine Model for Propofol in Greyhounds and Beagles T Abdulla, D Pade, S Neuhoff, M Jamei, MN Martinez Annual Meeting of the American Association of Pharmaceuical Scientists, San …, 2019 | | 2019 |
| Development and verification of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) dog model for Irbesartan following oral dose administration D Pade, S Neuhoff, K Abduljalil, M Jamei Annual Meeting of the American Association of Pharmaceuical Scientists, San …, 2019 | | 2019 |
| I-03: Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice K Abduljalil, RH Rose, D Pade, SK Chirumamilla, C Liu, I Taneja, ... PAGE 2019 Poster Abstracts, 19, 2019 | | 2019 |
Masoud JameiCertara UKGeverifieerd e-mailadres voor ieee.org
